Get the Stockscreener App
4.25
14.31%
-0.71
After Hours:
4.25
Cyclerion Therapeutics Inc stock is traded at $4.25, with a volume of 102.67K.
It is down -14.31% in the last 24 hours and up +21.08% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$4.96
Open:
$4.53
24h Volume:
102.67K
Relative Volume:
2.64
Market Cap:
$19.90M
Revenue:
$1.99M
Net Income/Loss:
$-5.28M
P/E Ratio:
-3.0961
EPS:
-1.3727
Net Cash Flow:
$-3.59M
1W Performance:
+12.14%
1M Performance:
+21.08%
6M Performance:
+205.76%
1Y Performance:
+77.82%
1-Day Range:
$4.08
$4.53
1-Week Range:
$3.545
$5.19
52-Week Range:
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
4.25 | 19.05M | 1.99M | -5.28M | -3.59M | -1.3727 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Therapeuticsinc Stock Price Forecast. Should You Buy CYCN? - StockInvest.us
Cyclerion Therapeutics Inc. (CYCN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cyclerion Therapeutics Inc. (CYCN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cyclerion Shareholders Approve Key Measures for Korsana Merger - TipRanks
Cyclerion TherapeuticsSets Sept 4, 2026 As Record Date For Cvr Distribution In Korsana MergerSEC Filing - TradingView
Cyclerion (NASDAQ: CYCN) sets CVR cutoff ahead of planned Korsana merger - Stock Titan
Balyasny Asset Management L.P. Initiates Position in Cyclerion T - GuruFocus
Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise - Stock Titan
Cyclerion (CYCN) CEO uses cashless exercise, forfeits 48,629 options - Stock Titan
Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership - Stock Titan
Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position - Stock Titan
Cyclerion (NASDAQ: CYCN) details Korsana merger plans and proxy materials - Stock Titan
Cyclerion Therapeutics (CYCN) outlines two-step merger structure with Korsana Biosciences - Stock Titan
Cyclerion Therapeutics (CYCN) outlines terms, risks and disclosures for proposed Korsana merger - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion FY26 Q2 net loss widens to $1.76 million; revenue falls to no revenue - Bitget
Cyclerion Therapeutics 2Q 2026: Revenue $0 Net loss $(1.76M) — 10-Q Summary - TradingView
Cyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk - stocktitan.net
Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Cyclerion Therapeutics (CYCN) Holds Flat at $3.49 as Shares Trade Within Established RangeMid Cap Momentum - dars.gov.et
Cyclerion Therapeutics (CYCN) Slides to $3.44 as Clinical-Stage Biotech Holds Key Support ZoneGap Down Bounce Plays - vinanet.vn
Cyclerion Therapeutics (CYCN) Slips 1.7% to $3.44 as Consolidation ContinuesCall Flow Alert - vinanet.vn
CYCN Q4 2025 Earnings: Narrower-Than-Expected Loss Beats Estimates as Cost Discipline Takes Center Stage - vinanet.vn
Cyclerion Therapeutics (CYCN) Stock Slides Slightly as It Tests Key Support LevelTWAP Entry - vinanet.vn
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics (CYCN) Slides 3.31% as Stock Tests Key Support LevelsRVOL Breakout - po-news-eg.net
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics Inc (CYCN) Balance Sheet - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Q4 2025 Earnings: Narrowing Losses Beat Expectations Amid Strategic Pipeline FocusFinancial Data - vinanet.vn
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock DeclinesManagement Tone Analysis - vinanet.vn
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneHidden Order - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55PCR Spike - dars.gov.et
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclerion Therapeutics Inc Stock (CYCN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Graul Regina Margaret | See Remarks |
Aug 14 '26 |
Option Exercise |
3.30 |
55,849 |
184,302 |
156,152 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):